- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Xetra | 102,500 | 27.09.24 13:40:50 | +0,160 | +0,16% | 102,320 | 102,400 | 101,860 | 102,340 |
|
REGENERON PHARMAC.DL-,001 | 881535 | Frankfurt | 932,800 | 27.09.24 11:36:52 | -0,200 | -0,02% | 922,200 | 933,200 | 927,000 | 933,000 |
